LB Pharmaceuticals (LBRX) Income Statement: Revenue & Earnings

LB Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

LB Pharmaceuticals Inc income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022
Period Ending	Dec 2024	Dec 2023	Dec 2022
Revenue & Gross Profit
Revenue	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00
Operating Expenses
Research & Development	51.17	7.85	1.35
Selling, General & Administrative	13.66	3.53	1.46
Operating Expenses	64.83	11.38	2.81
Operating Income	-64.83	-11.38	-2.81
Other Income/Expense
Interest Income	1.72	0.81	0.07
Interest Expense	0.00	4.83	2.15
Other Income/Expense	-0.95	9.12	-9.46
Income
Income Before Tax	-63.10	-6.27	-14.35
Income Tax Expense	0.00	0.00	0.00
Net Income	-63.10	-6.28	-14.35
Net Income - Continuous Operations	-63.10	-6.28	-14.35
Net Income - Discontinued Operations	0.00	0.00	0.00
EBITDA	-64.74	-1.45	-12.19
EBIT	-64.83	-1.45	-12.20
Depreciation & Amortization	0.09	0.00	0.00
Earnings Per Share
Basic EPS	-251.00	-2.00	-4.00
Diluted EPS	-251.00	-2.00	-4.00
Basic Shares Outstanding	0.25	3.54	3.54
Diluted Shares Outstanding	0.25	3.54	22.44